Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Congruence-Therapeuti

More Like This

Business Wire logo

YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency

ACCESS Newswire associated0

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

PR Newswire associated0

Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

Business Wire logo

Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

PR Newswire associated0

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability